ClinicalTrials.gg

Dermatomyositis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 184 studies for Dermatomyositis across more than 10 countries. 63 are recruiting or about to start. 122 of them are mainly about Dermatomyositis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
75
Recruiting
50
Status unknown
19
Terminated
14
Not yet recruiting
9
Active, not recruiting
8

Phase

Phase 2
61
Phase 3
31
Phase 1
29
Phase 4
9
Early Phase 1
5

Where

United States
94
France
31
China
31
Germany
22
Poland
20
Italy
20

Who develops what

Add Dermatomyositis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 16 programs from 12 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Bristol-Myers Squibb, AstraZeneca and Chongqing Precision Biotech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ULSC☆ Track1 live phase-3 study: NCT07160205Restem, LLC.

The 1 in phase 3 with the nearest primary completion, of 16 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Apr 2027 est.PN-101 · Paean Biotechnology Inc. · Phase 2 main aimNCT07122648 Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis — primary endpoint: International Myositis And Clinical Studies group-Total Improvement Score (IMACS-TIS) · 36 enrolled
  • Nov 2027 est.ruxoprubart · NovelMed Therapeutics · Phase 2 main aimNCT06887738 Study of NM8074 in Patients with Dermatomyositis (DM) — primary endpoint: Change from Baseline or Percent Change from Baseline in the number of patients whose Total Improvement Score (TIS) has increased by ≥ 20 · 8 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dermatomyositis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 3 open

Coming up

10studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10

Who these studies take

Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger. 15 (30%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (12%) take healthy volunteers.

Recruiting studies that take each age, of 50
AgeWomenMen
1013 (26%)13 (26%)
1847 (94%)47 (94%)
3048 (96%)48 (96%)
4048 (96%)48 (96%)
5048 (96%)48 (96%)
6545 (90%)45 (90%)
7536 (72%)36 (72%)
8532 (64%)32 (64%)

Across all 184 studies, recruiting or not: 38% stop at 75 or younger and 21% at 65; 33% take children; 1% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dermatomyositis studies take

Of 19 phase 2 interventional studies under Dermatomyositis, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 231 mo28–52 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 184. Browse all 184 → or search them.